Quantum-Si incorporated QSI

Company Overview

Quantum-Si Incorporated is a U.S.-based life sciences and biotechnology company focused on next-generation protein sequencing and proteomics tools. The company operates within the broader genomics, proteomics, and molecular diagnostics industries, with a primary emphasis on enabling single-molecule protein analysis through semiconductor-based sequencing technology. Quantum-Si’s core commercial platform is the Platinum® protein sequencing system, which is designed to make proteomic analysis more accessible to academic researchers, pharmaceutical companies, translational medicine organizations, and clinical research institutions. Revenue has historically been derived from instrument sales, consumables, service agreements, and related research-use products.

The company positions itself as an early mover in semiconductor-enabled protein sequencing, seeking to extend concepts that transformed DNA sequencing into the proteomics field. Quantum-Si was founded in 2013 by Jonathan Rothberg, who also founded several genomic technology companies, including 454 Life Sciences. The company became publicly traded in 2021 through a merger with special purpose acquisition company HighCape Capital Acquisition Corp. Since commercialization efforts began, Quantum-Si has focused on expanding adoption of benchtop proteomics tools intended to lower complexity and cost barriers associated with traditional mass spectrometry workflows.